Safety assessment of adjuvanted vaccines: Methodological considerations

References

• Baylor N, Midthun K. Regulation and Testing of Vaccines. In: Plotking SA, Orenstein WA, eds. Vaccines 5th ed. Philadelphia: Saunders; 2004
   Google Scholar
• Freed GL, Katz SL, Clark SJ. Safety of vaccinations. Miss America, the media, and public health. JAMA J Am Med Assoc 1996; 276:1869-72; http://dx.doi.org/10.1001/jama.1996.03540230019013
   PubMed Web of Science ®Google Scholar
• Ward BJ. Vaccine adverse events in the new millennium: is there reason for concern? Bull WHO 2000; 78:205-15; PMID:10743286
   PubMed Web of Science ®Google Scholar
• Song G. Understanding public perceptions of benefits and risks of childhood vaccinations in the United States. Risk Anal Off Publ Soc Risk Anal 2014; 34:541-55; http://dx.doi.org/10.1111/risa.12114
   PubMed Web of Science ®Google Scholar
• Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, Chen RT. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351:356-61; PMID:9652634; http://dx.doi.org/10.1016/S0140-6736(97)04334-1
   PubMed Web of Science ®Google Scholar
• Whooping cough (pertussis) statistics – Publications – GOV.UK.; [cited 2014 Nov 21]; Available from: https://www.gov.uk/government/publications/whooping-cough-pertussis-statistics
   Google Scholar
• Amirthalingam G, Gupta S, Campbell H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2013; 18:20587; PMID:24084340
   PubMedGoogle Scholar
• Majumder MS, Cohn EL, Mekaru SR, Huston JE, Brownstein JS. Substandard Vaccination Compliance and the 2015 Measles Outbreak. JAMA Pediatr 2015; 169(5):494-495; PMID:25774618
   PubMed Web of Science ®Google Scholar
• Garcon N, Leroux-Roels G, Cheng W. Vaccine adjuvants. In: Understanding Modern Vaccines: Perspectives in Vaccinology. Elsevier; 2011. 89-113
   Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723-39; PMID:17931153; http://dx.doi.org/10.1586/14760584.6.5.723
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287-93; PMID:19247370; http://dx.doi.org/10.1038/nri2510
   PubMed Web of Science ®Google Scholar
• Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013; 12:747-58; PMID:23885820; http://dx.doi.org/10.1586/14760584.2013.811188
   PubMed Web of Science ®Google Scholar
• Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines 2013; 12:779-91; PMID:23885823; http://dx.doi.org/10.1586/14760584.2013.811195
   PubMed Web of Science ®Google Scholar
• Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012; 11:349-66; PMID:22380826; http://dx.doi.org/10.1586/erv.11.192
   PubMed Web of Science ®Google Scholar
• Garçon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs Clin Immun Biopharm Gene Ther 2011; 25:217-26; PMID:21815697
   PubMedGoogle Scholar
• Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert P-H, Reisinger K, Haupt RM. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010; 28:4719-30; PMID:20451636; http://dx.doi.org/10.1016/j.vaccine.2010.04.070
   PubMed Web of Science ®Google Scholar
• Angelo M-G, Taylor S, Struyf F, Tavares Da Silva F, Arellano F, David M-P, Dubin G, Rosillon D, Baril L. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine. Expert Rev Vacc 2014; 13:1297-306; http://dx.doi.org/10.1586/14760584.2014.959931
   PubMed Web of Science ®Google Scholar
• Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol Baltim Md 1950 2004; 173:4627-34
   Google Scholar
• Wood N, Siegrist C-A. Neonatal immunization: where do we stand? Curr Opin Infect Dis 2011; 24:190-5; PMID:21415741; http://dx.doi.org/10.1097/QCO.0b013e328345d563
   PubMed Web of Science ®Google Scholar
• Panda A, Qian F, Mohanty S, van Duin D, Newman FK, Zhang L, Chen S, Towle V, Belshe RB, Fikrig E, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol Baltim Md 1950 2010; 184:2518-27
   Google Scholar
• Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007; 211:144-56; PMID:17200946; http://dx.doi.org/10.1002/path.2104
   PubMed Web of Science ®Google Scholar
• La Rocca C, Carbone F, Longobardi S, Matarese G. The immunology of pregnancy: Regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett 2014; 162:41-8; http://dx.doi.org/10.1016/j.imlet.2014.06.013
   PubMed Web of Science ®Google Scholar
• Waruiru C, Appleton R. Febrile seizures: an update. Arch Dis Child 2004; 89:751-6; PMID:15269077; http://dx.doi.org/10.1136/adc.2003.028449
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, Jackson LA, Tse A, Belongia EA, Hambidge SJ, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr 2013; 167:1111-7; PMID:24126936; http://dx.doi.org/10.1001/jamapediatrics.2013.2745
   PubMed Web of Science ®Google Scholar
• Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. J Infect Dis 2014; 209 3:S114-9; PMID:24966191; http://dx.doi.org/10.1093/infdis/jiu066
   PubMedGoogle Scholar
• Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines 2014; 13:399-415; PMID:24512188; http://dx.doi.org/10.1586/14760584.2014.883285
   PubMed Web of Science ®Google Scholar
• Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med 1997; 151:255-9; PMID:9080932; http://dx.doi.org/10.1001/archpedi.1997.02170400041007
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. Food Drug Admin 1997. [cited 2014 Jul 27]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM175909.pdf
   Google Scholar
• European Medicines Agency. Committee for medicinal products for human use. Guideline on Clinical Evaluation of New Vaccines. London: 2006; [cited 2014 Jul 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003870.pdf
   Google Scholar
• European Medicines Agency. Committee for medicinal products for human use. Guideline on Adjuvants in Vaccines for Human Use. London: 2005; [cited 2014 Jul 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003809.pdf
   Google Scholar
• Gruber M. Regulatory Pathways Supporting Development and Approval of Vaccines formulated with Novel Adjuvant: Regulatory Considerations and Challenges. 2012; [cited 2014 Jul 28]; Available from: http://www.fda.gov/downloads/EmergencyPreparedness/MedicalCountermeasures/UCM292045.pdf
   Google Scholar
• Report to the FDA Commissioner From the Task Force on Risk Management. Safety of specific products – current risk management for medical products.; [cited 2014 Oct 6]; Available from: http://www.fda.gov/Safety/SafetyofSpecificProducts/ucm180580.htm
   Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010; 28 3:C25-36; PMID:20713254; http://dx.doi.org/10.1016/j.vaccine.2010.07.021
   PubMedGoogle Scholar
• WHO | Global pandemic influenza action plan to increase vaccine supply. WHO; [cited 2012 Apr 1]; Available from: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_1/en/index.html
   Google Scholar
• Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, et al. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013; 13:435; PMID:24041010; http://dx.doi.org/10.1186/1471-2334-13-435
   PubMed Web of Science ®Google Scholar
• Schijns VEJC, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011; 10:539-50; PMID:21506650; http://dx.doi.org/10.1586/erv.11.21
   PubMed Web of Science ®Google Scholar
• Mount A, Koernig S, Silva A, Drane D, Maraskovsky E, Morelli AB. Combination of adjuvants: the future of vaccine design. Expert Rev Vaccines 2013; 12:733-46; PMID:23885819; http://dx.doi.org/10.1586/14760584.2013.811185
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505-17; PMID:17558426; http://dx.doi.org/10.1038/nrmicro1681
   PubMed Web of Science ®Google Scholar
• Shanks N, Greek R, Greek J. Are animal models predictive for humans? Philos Ethics Humanit Med PEHM 2009; 4:2; http://dx.doi.org/10.1186/1747-5341-4-2
   PubMedGoogle Scholar
• European Medicines Agency.: Committee for Proprietary Medicinal Products. Note for guidance on preclinical pharmacological and toxicological testing of vaccines London: 1997; [cited 2014 Jul 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004004.pdf
   Google Scholar
• WHO. World health Organization. Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines. Switzerland: 2013; [cited 2014 Oct 8]. Available from: http://www.who.int/biologicals/areas/vaccines/ADJUVANTS_Post_ECBS_edited_clean_Guidelines_NCE_Adjuvant_Final_17122013_WEB.pdf
   Google Scholar
• Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, Fritzell B. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biol J Int Assoc Biol Stand 2013; 41:458-68
   Google Scholar
• Destexhe E, Grosdidier E, Baudson N, Forster R, Gerard C, Garçon N, Segal L. Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys. 2015; 35:717-28
   Google Scholar
• Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011; 29:4453-9; PMID:21527299; http://dx.doi.org/10.1016/j.vaccine.2011.04.046
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Bonanni P, Tantawhichien T, Zepp F. Vaccine Development. In, Understanding Modern Vaccines: Perspectives in Vaccinology. Garcon N, Stern PL, Cunningham AL, Stanberry LR, eds. Elsevier B.V; 2011
   Google Scholar
• Crowe BJ, Xia HA, Berlin JA, Watson DJ, Shi H, Lin SL, Kuebler J, Schriver RC, Santanello NC, Rochester G, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials Lond Engl 2009; 6:430-40; http://dx.doi.org/10.1177/1740774509344101
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48:1007; PMID:10577495
   PubMedGoogle Scholar
• Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa052434
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009; 28:345-51; PMID:19879226; http://dx.doi.org/10.1016/j.vaccine.2009.10.041
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rotavirus. Vaccine Saf 2014. [cited 2015 Jan 6]; Available from: http://www.cdc.gov/vaccinesafety/vaccines/rotavsb.html
   Google Scholar
• Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21:298-302; PMID:12450705; http://dx.doi.org/10.1016/S0264-410X(02)00449-8
   PubMed Web of Science ®Google Scholar
• Kohl KS, Magnus M, Ball R, Halsey N, Shadomy S, Farley TA. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. Vaccine 2008; 26:6349-60; PMID:18805456; http://dx.doi.org/10.1016/j.vaccine.2008.09.002
   PubMed Web of Science ®Google Scholar
• Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009; 227:248-63; PMID:19120489; http://dx.doi.org/10.1111/j.1600-065X.2008.00733.x
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823-35; PMID:17063184; http://dx.doi.org/10.1038/nri1957
   PubMed Web of Science ®Google Scholar
• Tavares Da Silva F, De Keyser F, Lambert P-H, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013; 31:1870-6; PMID:23391600; http://dx.doi.org/10.1016/j.vaccine.2013.01.042
   PubMed Web of Science ®Google Scholar
• Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep 2007; 30:13-26; PMID:17310860
   PubMed Web of Science ®Google Scholar
• Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70:410-7; PMID:21866560; http://dx.doi.org/10.1002/ana.22587
   PubMed Web of Science ®Google Scholar
• De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, et al. CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy. Sci Transl Med 2013; 5:216ra176; PMID:24353159
   PubMed Web of Science ®Google Scholar
• Van der Most R, Van Mechelen M, Destexhe E, Wettendorff M, Hanon E. Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal. Hum Vaccines Immunother 2014; 10:572-6; http://dx.doi.org/10.4161/hv.27412
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination. A multi-country European Epidemiological Investigation. Stockholm: ECDC; 2012
   Google Scholar
• Langmuir AD. Guillain-Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976–77: preliminary communication. J R Soc Med 1979; 72:660-9; PMID:552571
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 1979; 110:105-23; PMID:463869
   PubMed Web of Science ®Google Scholar
• Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine 2013; 31:4448-58; PMID:23770307; http://dx.doi.org/10.1016/j.vaccine.2013.06.032
   PubMed Web of Science ®Google Scholar
• Isai A, Durand J, Le Meur S, Hidalgo-Simon A, Kurz X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine 2012; 30:7123-9; PMID:23022149; http://dx.doi.org/10.1016/j.vaccine.2012.09.032
   PubMed Web of Science ®Google Scholar
• Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, Andrews N, Svanström H, Mølgaard-Nielsen D, Hviid A, et al. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PloS One 2014; 9:e82222; PMID:24404128; http://dx.doi.org/10.1371/journal.pone.0082222
   PubMed Web of Science ®Google Scholar
• Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227-9; PMID:11207170; http://dx.doi.org/10.1136/adc.84.3.227
   PubMed Web of Science ®Google Scholar
• Sauvé LJ, Scheifele D. Do childhood vaccines cause thrombocytopenia? Paediatr Child Health 2009; 14:31-2; PMID:19436461
   PubMedGoogle Scholar
• Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur J Intern Med 2010; 21:70-3; PMID:20206873; http://dx.doi.org/10.1016/j.ejim.2009.12.001
   PubMed Web of Science ®Google Scholar
• WHO | Statement from the Global Advisory Committee on Vaccine Safety on aluminium-containing vaccines. WHO; [cited 2014 Mar 20]; Available from: http://www.who.int/vaccine_safety/committee/topics/aluminium/statement_112002/en/
   Google Scholar
• Wraith DC, Goldman M, Lambert P-H. Vaccination and autoimmune disease: what is the evidence? Lancet 2003; 362:1659-66; PMID:14630450; http://dx.doi.org/10.1016/S0140-6736(03)14802-7
   PubMed Web of Science ®Google Scholar
• Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007; 120:506-15; PMID:17765751; http://dx.doi.org/10.1016/j.jaci.2007.07.033
   PubMed Web of Science ®Google Scholar
• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain J Neurol 2006; 129:1953-71; http://dx.doi.org/10.1093/brain/awl075
   Web of Science ®Google Scholar
• Offit P, Davis RL, Gust D. Safety of immunizations. In Vaccines. Plotkin SA, Orenstein WA, Offit PA eds. Philadelphia: Elsevier B.V; 2008
   Google Scholar
• Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009; 9:418-27; PMID:19555901; http://dx.doi.org/10.1016/S1473-3099(09)70132-X
   PubMed Web of Science ®Google Scholar
• De Martino M, Chiappini E, Galli L. Vaccines and autoimmunity. Int J Immunopathol Pharmacol 2013; 26:283-90; PMID:23755743
   PubMed Web of Science ®Google Scholar
• Angelo M-G, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014; 23:456-65; PMID:24644078; http://dx.doi.org/10.1002/pds.3593
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Descamps D, David M-P, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630-8; PMID:18845199; http://dx.doi.org/10.1016/j.vaccine.2008.09.049
   PubMed Web of Science ®Google Scholar